AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Precigen, Inc.
Video analysis: PGEN
All videosNo video analysis for this stock yet. Request one from our team.
News: PGEN
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
Legal & General Group Plc Takes $730,000 Position in Precigen, Inc. $PGEN
Legal and General Group Plc purchased a new stake in Precigen, Inc. (NASDAQ: PGEN) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 128,048 shares of the biotechnology company's stock, valued at approximately $730,000. A number of other hedge funds have
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the Broader Potential of Its Proprietary AdenoVerse Therapeutic Platform in HPV-Associated Cancers GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.
Reasons Why Investors Should Consider Betting on PGEN Stock
Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.
Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Precigen: Has To Grow Into Its Valuation
Precigen surged 266% on PAPZIMEOS FDA approval but now trades at a premium valuation near $2.24 billion. PAPZIMEOS, the sole revenue driver, reached $53.1 million in Q2 with COGS being just around $2.8 million. PGEN's pipeline faces stiff competition, with most candidates showing weaker efficacy than approved or late-stage rivals.
